Rationale: Every year, about 40,000 people in the Netherlands have a stroke. After the initial admission to the hospital, about 15% of stroke survivors is admitted to a rehabilitation center because of remaining disabilities. Three out of four of these patients have upper limb dysfunction, hampering activities of daily living. Upper limb function plays a critical role in the performance of most daily life activities. In our phase II trial B-STARS, continuous theta burst stimulation (cTBS) treatment led to an absolute additional recovery of upper limb function of 17%, as measured with the Action Research Arm Test (ARAT) score three months after stroke. This improvement exceeds the minimal clinically important difference of 10%. cTBS treatment also resulted in a significant improvement in measures of activities and participation (of similar magnitude) and a reduction in the mean length of stay at the rehabilitation center by 18 days. Objective: To assess the effectiveness and cost effectiveness of cTBS treatment in promoting upper limb recovery after stroke in patients admitted to a rehabilitation center. Study design: A phase III, multi-center, double-blind, randomized, sham-controlled, clinical trial. Study population: 454 patients aged 18 years or older with a first-ever ischemic stroke or intracerebral hemorrhage and a unilateral arm paresis, defined by a Motricity Index between 9 and 99, in whom cTBS treatment can be started within 3 weeks after stroke onset. Intervention: 10 daily sessions of cTBS delivered over the contralesional primary motor cortex during a period of 2 weeks, delivered immediately before regular care physical therapy of the affected upper limb. Main study parameters/endpoints: The primary endpoint will be the score on the upper extremity section of the Fugl-Meyer assessment (FM-UE) at 90 days after stroke. Secondary endpoints will include the score on the FM-UE at one year and the scores on the Action Research Arm Test, Nine Hole Peg Test, Stroke Impact Scale, EuroQol 5 Dimensions and modified Rankin Scale at 90 days and one year after stroke
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
454
10 sessions of active cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
10 sessions of sham cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
Tolbrug
's-Hertogenbosch, Netherlands
NOT_YET_RECRUITINGReade
Amsterdam, Netherlands
RECRUITINGRevalidatie Friesland
Beetsterzwaag, Netherlands
RECRUITINGRevant
Breda, Netherlands
RECRUITINGMRC Aardenburg
Doorn, Netherlands
NOT_YET_RECRUITINGLibra Blixembosch
Eindhoven, Netherlands
RECRUITINGUniversity Medical Center Groningen
Groesbeek, Netherlands
NOT_YET_RECRUITINGMerem
Hilversum, Netherlands
RECRUITINGAdelante
Hoensbroek, Netherlands
RECRUITINGBasalt
Leiden, Netherlands
RECRUITING...and 6 more locations
Upper extremity section of the Fugl-Meyer Assessment
The score ranges from 0 to 66 points with a higher score indicating better outcome
Time frame: at 90 days post-stroke
Upper extremity section of the Fugl-Meyer Assessment
The score ranges from 0 to 66 points with a higher score indicating better outcome
Time frame: at 12 months post-stroke
Action Research Arm Test
The score ranges from 0 to 57 points with a higher score indicating better outcome
Time frame: at 90 days and 12 months post-stroke
modified Rankin Scale
The score ranges from 0 to 6 points with a lower score indicating better outcome
Time frame: at 90 days and 12 months post-stroke
Hand section of Stroke Impact Scale
The score ranges from 0 to 25 points with a higher score indicating better outcome
Time frame: at 90 days and 12 months post-stroke
Participation section of Stroke Impact Scale
The score ranges from 0 to 40 points with a higher score indicating better outcome
Time frame: at 90 days and 12 months post-stroke
EuroQol-5D
The score ranges from 0 to 5 points per item with a higher score indicating better outcome
Time frame: at 90 days and 12 months post-stroke
Nine Hole Peg Test
The outcome ranges from 0 to 50 seconds with a shorter outcome indicating better outcome
Time frame: at 90 days and 12 months post-stroke
Ipsilesional corticospinal excitability
Ipsilesional corticospinal excitability is defined as the resting motor threshold of the ipsilesional hemisphere as determined with single pulse TMS. The outcome ranges from 0 to 100% of the machine output
Time frame: within 12 hours after the 10th cTBS session
iMTA medical consumption questionnaire
This questionnaire aims to identify costs associated with medical consumption
Time frame: at 6 and 12 months post-stroke
iMTA productivity cost questionnaire
This questionnaire aims to identify costs associated with productivity loss of paid work.
Time frame: At 6 and 12 months post-stroke
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.